ARTICLE | Company News
Dor BioPharma, BL&H Co. Ltd. sales and marketing update
February 25, 2008 8:00 AM UTC
The companies signed a letter of intent for BL&H to distribute Dor's orBec beclomethasone dipropionate to treat acute gastrointestinal graft-versus-host disease (GvHD) as part of the Korea Orphan Drug Center's (KODC) compassionate use program. The companies will share revenues. BL&H will be responsible for distribution expenses in South Korea. Further terms were not disclosed. ...